IPO action brief: SK hynix gets terms, TARX hits Thursday
SK hynix is now the headline US IPO watch after filing terms for a roughly $28.1 billion Nasdaq ADS offering. The brief separates verified calendar facts from unverified broker access, flags Tarsier Pharma's Thursday debut, and keeps Hong Kong to post-subscription allotment signals rather than calling a closed deal actionable.
SK hynix is no longer just a calendar name. The Korean memory giant has filed terms for a Nasdaq ADS offering that could raise about $28.1 billion, while the only smaller operating-company debut on this week's public calendars is Tarsier Pharma. The practical retail takeaway is still simple: no mainstream US retail allocation window was publicly verifiable before the open today.
Today's Spotlight: SK hynix
SK hynix plans to offer 177.9 million ADSs on Nasdaq under the symbol SKHY, with each ADS representing one-tenth of a common share. Its July 6 amended F-1 says the reference price was $158.14 per ADS, tied to the July 3 Korea closing price, and that the ADSs have applied to list on the Nasdaq Global Select Market. 1
Why it matters: this is not a speculative pre-revenue IPO. SK hynix says it ranked No. 1 in high-bandwidth memory revenue in the first quarter of 2026 with a 56.4% share, and HBM is the memory category most tied to AI server demand. 1
The headline number: Renaissance Capital lists the deal size at $28.133 billion and says SK hynix is expected to price in the week of July 6. 2
The key risk: memory chips are cyclical. SK hynix itself flags recurring oversupply, pricing swings, competition, customer concentration, export controls, and AI-demand slowdown as risk factors. In plain English: the AI angle is real, but this is still a boom-and-bust chip business. 1
Subscription status: public sources confirm the offering terms and expected trading window, but they do not confirm access through Robinhood, Fidelity, Schwab, E*TRADE, or Webull. Treat SKHY as watch-only unless your broker shows an actual order ticket.
Actionable Now
The US market is open today: July 8 is not listed as a 2026 NYSE market holiday, and the next listed full closure after Independence Day observed is Labor Day on September 7. 3
| IPO | Ticker | Terms | Expected trade date | Broker access today | Retail read |
|---|---|---|---|---|---|
| SK hynix | SKHY | 177.9M ADSs at reference price of $158.14; about $28.1B deal size | July 10 | Not publicly verified | Biggest name on the board; AI memory exposure, but no verified retail allocation window. 4 |
| Tarsier Pharma | TARX | 5.0M shares at $8-$10; about $45M deal size | July 9 | Not publicly verified | Small Phase 3 eye-disease biotech; higher binary clinical risk than a scaled operating company. 5 |
| Bleichroeder Acquisition Corp. III | BCCQU | 30.0M units at $10; $300M SPAC IPO | Priced July 7; expected to close July 8 | Already trading as units, not a retail subscription window | A SPAC unit, not the same decision as buying into an operating-company IPO allocation. 6 |
Market Pulse
- Cornerstone demand is the SKHY signal. SK hynix says Baillie Gifford, Coatue, and Situational Awareness Partners indicated interest in up to $7 billion of ADSs. These are not binding commitments, but they are a serious institutional demand marker. 1
- SPAC issuance is still active. SPACInsider says Bleichroeder III brought 2026 year-to-date SPAC deal count to 121 after pricing its $300 million IPO. For retail investors, that means the IPO calendar has volume, but not all volume is operating-company exposure. 6
- HK demand is showing up in allotments, not new subscriptions. Momenta's Hong Kong public offering was reported as 413.63 times subscribed, with trading beginning July 8 under stock code 6880. The official HKEX PDF link was discoverable but did not provide a readable allotment table at publication time, so treat this as a supplemental signal rather than a primary-source replacement. 7
HK Desk
No new Hong Kong public subscription window was verified from accessible primary pages during this run. The fresh HK item is post-subscription: Momenta's allotment result and first trading day. The reported final offer price was HK$295.60, the board lot was 20 shares, and trading was scheduled to begin on July 8. 7
For action: this is no longer a subscription decision. It is a secondary-market trading decision, with the main watchpoint being demand after a heavy oversubscription headline.
On The Radar
| Name | Ticker | Window | Why retail investors should watch |
|---|---|---|---|
| Csquare | CSQR | Expected July 16 | $23-$27 range and about $1.25B deal size; data-center angle keeps it close to the AI infrastructure trade. 8 |
| Standard Nuclear | STDN | Expected July 16 | $18-$21 range and about $356M deal size; nuclear remains a retail-friendly energy theme, but terms still need broker access checks. 8 |
| MetaOptics | MOT | Week of July 13 | Small uplisting at a $5-$7 range; likely too small for broad retail allocation, but worth watching for volatility. 8 |
Bottom line: SKHY is the headline, TARX is the small-cap biotech debut, and verified retail order access remains the missing piece. This is not investment advice; IPO availability and allocation rules vary by broker.
References
- 1SK hynix amended Form F-1
sec.gov
- 2Renaissance Capital SK hynix IPO news
renaissancecapital.com
- 3NYSE holidays and trading hours
nyse.com
- 4IPOScoop SK hynix profile
iposcoop.com
- 5IPOScoop Tarsier Pharma profile
iposcoop.com
- 6SPACInsider Bleichroeder III pricing
spacinsider.com
- 7Minichart Momenta allotment summary
minichart.com.sg
- 8Renaissance Capital IPO calendar
renaissancecapital.com
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.